Business Wire

BEARINGPOINT

24.11.2022 13:16:34 CET | Business Wire | Press release

Share
BearingPoint: New Mobility Players to Change the Competitive Landscape as Personal Mobility Shifts to Services From Ownership

Management and technology consultancy BearingPoint’s latest study suggests mobility decisions will be very different by 2030. The study, “Destination 2030, Who’s in the driving seat for the future of mobility?” identified three trends that will drive mobility in the coming years:

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221124005066/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Destination 2030 - who’s in the driving seat for the future of mobility? (Graphic: Business Wire)

1.) every journey will become a personalized experience

2.) climate neutrality will be non-negotiable – from the cradle to the grave

3.) users will consume services rather than own vehicles.

“It will be a radically different mobility ecosystem that will affect automotive manufacturers, transportation providers, and even energy suppliers as well as tech and insurance companies. What changes is how services are provided and consumed, and these industries must start preparing now. The growth of personalized mobility, mobility as a service and the push towards carbon-neutrality will all profoundly impact the way we think about travel. We’ll control our travel experiences in a new way, and this will impact our relationship with car brands, potentially weakening their ownership of us as customers,” said Dr. Stefan Penthin, global leader Automotive, Industrial Equipment & Manufacturing at BearingPoint.

Remote work, energy crises, climate change and supply chain disruptions are profoundly changing the demand for mobility

The study drew from BearingPoint’s internal research, the views of clients across all industry sectors and input from the consultancy’s sector and technology leaders. The study says remote work, energy crises, climate change and supply chain disruptions are profoundly changing the demand for mobility and the direction and pace of change.

“87% of the survey participants believe they will commute less frequently to work and 81% said they will take significantly fewer business trips compared to 2019, and if this trend continues, it will impact investment in infrastructure. The increased costs associated with developing new mobility infrastructure cannot be passed on entirely to the end user. Legislation may also need to be implemented to achieve the right infrastructure to support electric vehicles. Licensing and enforcement will shift focus from the individual to the provider,” said Andrew Montgomery, global leader Government and Public Sector at BearingPoint.

Three trends that will drive mobility in the coming years

The study sees every journey becoming a personalized experience. Public transportation will shift toward individual mobility, with schedules dictated by consumer needs, rather than predefined as with traditional public transportation. This will lead to more user-centric offerings, making traveling time more productive.

Climate neutrality will be non-negotiable, according to the study, which points to 80% of manufactured engines being green by 2030. Investment will increase in zero-impact modes and related infrastructure, particularly those that promote well-being, such as walking and cycling. And half of the participants (49%) say that they would sacrifice vehicle ownership to reduce their environmental footprint by 2030.

As users will consume services rather than own vehicles, they will switch to on-demand services rather than owning an underutilized vehicle. The services and software will be more important to the general consumer than the physical vehicle and brand, as software platforms will orchestrate the entire journey. 81% of participants point out that they will prefer to use one single app/platform for ordering and billing all their mobility-related services. The study also sees new entrants as constructors, not disruptors.

For more details, please read the full article here: https://www.bearingpoint.com/en/insights-events/insights/destination-2030/

About BearingPoint

BearingPoint is an independent management and technology consultancy with European roots and a global reach. The company operates in three business units: Consulting, Products, and Capital. Consulting covers the advisory business with a clear focus on selected business areas. Products provides IP-driven digital assets and managed services for business-critical processes. Capital delivers M&A and transaction services.

BearingPoint’s clients include many of the world’s leading companies and organizations. The firm has a global consulting network with more than 13,000 people and supports clients in over 70 countries, engaging with them to achieve measurable and sustainable success.

For more information, please visit:

Homepage: www.bearingpoint.com
LinkedIn: www.linkedin.com/company/bearingpoint
Twitter: @BearingPoint

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221124005066/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release

Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie

Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release

Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie

IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release

IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi

Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release

Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M

Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release

Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye